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1. Introduction
Drug review procedure and drug development strategies are changing rapidly due to “The
International Conference on Harmonisation of Technical Requirements for the Registration of
Pharmaceuticals for Human Use ”, which was initiated in 1990 (ICH, 1990). The ICH seeks for
improvement of the efficiency of the development and review processes for promising new drugs
by unifying necessary documentation and its associated formats for new drug applications (NDA)
to regulatory agencies. In particular, E5 guideline regarding ethnic factors in the acceptability of
foreign clinical data has asignificant impact on anew drug’s development by allowing the
extrapolation of foreign clinical data as apart of an NDA submission to the regulatory agency in a
new region (ICH, 1998). In the extrapolation of the foreign clinical data to the new regions, a
population pharmacokinetics study (PPK) is valuable for the evaluation of pharmacokinetics
parameters in order to investigate intrinsic factors among populations. In the population
pharmacokinetics studies, the two types of the statistical analyses are commonly employed. We
will investigate the statistical properties of the analyses through simulation studies.
2. Definition and Properties
For each subject $i$, $1\leq i\leq N$ , $n_{i}\cross 1$ observation vector, $\mathrm{y}_{i}$ , will follow anonlinear mixed




where $f(X_{i},\beta_{i})$ is anonlinear function ofpharmacokinetics model $\beta_{i}$ is an individual
$r\mathrm{x}1$ vector ofregression coefficients. $X_{i}$ is aknown $n_{i}\cross t$ design matrix. 7is a $r\mathrm{x}1$
fixed effects parameters $b_{i}$ is a $r\cross 1$ random effects parameter$\mathrm{s}_{\backslash }\epsilon_{i}$ is a $n_{i}\cross 1$ vector of
error terms. We assume that $b_{i}$ is normaly distributed with amean 0, covariance
matrix $\Psi$ denoted by, $N(0,\Psi_{r\mathrm{x}r})$ , $\epsilon_{i}$ is normally distributed with mean 0, covariance
matrix $\sigma^{2}\Lambda_{i}(\gamma)$ denoted by, $N(0,\sigma^{2}\Lambda_{i}(\gamma)_{n.\mathrm{x}n_{i}}.)$ , where $\gamma$ are unknown parameters. We
assume $\mathrm{t}\mathrm{h}\mathrm{a}\mathrm{t}b_{i}$ and $\epsilon$, are mutually independent. Our main goal is an estimation offixed
effects parameter $\beta$ . Therefore we need to know its marginal distribution of
individual observations.
Define $\mathrm{t}\mathrm{h}\mathrm{a}\mathrm{t}P(\mathrm{y}_{i}|b_{i})$ and $P(b_{i})\mathrm{a}re$ probability density functions of $\mathrm{y}_{i}|b_{i}$ andb. The
marginal density function of $\mathrm{y}_{j}$ , $P(y${, can be defined as
$P( \mathrm{y}_{i})=\int P(\mathrm{y}_{i}|b_{i})P(b_{i})db_{i}$ (2)
In contrast to alinear mixed effects model (Laird and Ware, 1982), their expected
values of the observed data are nonlnear functions of both the fixed effects and the
random effects. In general there is no closed forms existed. Commonly two types of the
$1^{\epsilon \mathrm{t}}$ order Taylor expansion are employed in order to get the closed forms. The first
approximation method is the $1^{\epsilon \mathrm{t}}$ order Taylor expansion around its expected values, 0
(Sheiner and Beal, 1980, 1985, Vonesh and Carter, 1992) and the second
approximation method is the $1^{s\mathrm{t}}$ order Taylor expansion around its estimated values of
the random effects, $\hat{b}_{i}$ (Lindstrom and Bates, 1990).






Then the observed data can be approximated as
$\mathrm{y}_{i}=f(X_{i},\beta,b_{i}=0)-Z_{i}b_{i}+\epsilon_{i}$ (4)
It can be shown that the expected values of the observed data, $E[\mathrm{y}_{i}]$ , and the variance,
$Var[\mathrm{y}_{i}]$ , can be written as
$E[\mathrm{y}_{i}]=f(X_{i},\beta,b_{i}=0)=f(X_{i},\beta)$ (5)
$Var[\mathrm{y}_{i}]=Z_{i}\Psi Z_{i}^{T}+\sigma^{2}\Lambda_{i}(\gamma)$ (6)
The expected values are only functions of the fixed effects, and the variance are
functions of both the fixed effects and the random effects. Two points are noteworthy to
mention in this Taylor expansion: (1) this approximation is appropriate when the
variance of the random effects, $b_{i}$ , $Var[b_{i}]$ , is very small so that we can ignore
individual variations (Solomon and Cox, 1992) and (2) the expected values of the
marginal distribution must be correctly specified for inference of its covariance
parameters, $\gamma$ and $\sigma^{2}$ (Breslow and Clayton, 1993).
The other Taylor expansion around the estimated random values, $\hat{b}_{i}$ , of the
observed values can be defined as
$\mathrm{y}_{i}=f(X_{i},\beta,b_{i}=\hat{b}_{i})-[\frac{\partial f}{\delta b_{i}^{T}}|_{b_{i}=\hat{t}_{j}}](b_{i}-\hat{b}_{i})+\epsilon_{i}$ (7)
where
$Z_{i}^{*}$
Then the expected values and its covariance can be written as follows:
$E[\mathrm{y}_{i}]=f(X_{i},\beta,b_{i}=\hat{b}_{i})-Z_{i}^{*}\hat{b}_{i}$ (8)
$Var[\mathrm{y}_{i}]=Z_{i}^{*}\Psi Z_{i}^{*T}+\sigma^{2}\Lambda_{i}(\gamma)$ $(9\rangle$
In contrast to the results derived ffom the Taylor expansion around the expected
values, 0both the expected values and its covariance are function of the estimated
random value, $\hat{b}_{i}$ . These results will influence an asymptotic distribution of
estimators, $\hat{\beta}$ , of the fixed effects. The likelihood function derived ffom the Taylor
expansion around the estimated random values, $\hat{b}_{i}$ , can be derived by Laplac
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approximation (Wolfinger, 1993, Vonesh, 1996). It can be shown that the required
condition for consistency can be given as
(10)$\hat{\beta}-\beta=O_{p}[\max\{\frac{1}{\sqrt{N}},$ $\frac{1}{\min(n_{i})}\}]$
(Vonesh, 1996). The condition indicates that an increasing rate of asample size and of
observations per subject must be constant in order to obtain the consistency of $\hat{\beta}$ .
It is well known that population pharmacokinetics analysis is suitable to data
consisting of afew data points per subject from many individuals. We can apply the
first order Taylor expansion around the expected values, 0, when we can ignore the
variability among individuals, i.e., $Var[b_{i}]$ . In that case we require alarge number of
individuals, $N$, with few data points per subject, $I\mathit{1}_{j}$ for the consistency of $\hat{\beta}$ . On the
other hand, the main purpose of population pharmacokinetics analysis is to estimate
population parameters adjusting for variability among subjects, $Var[b_{i}]$ . The first
order Taylor expansion around the estimated random effects, $\hat{b}_{i}$ , is appropriate in this
case. This method requires alarge number of observations per individual, which is
contradict to the merit of population pharmacokinetics analysis requiring few
observations per subject from many individuals for the consistency of the population
parameters. We investigate behaviors of the estimated population parameters, 7,
influenced by either atotal sample size, $N$, or observations per subject, $I2_{\dot{p}}$ depending
on adegree of $Var[bl,]$ through simulation studies. Finaly we consider an appropriate
study design in clinical trial settings.
3. Simulation Studies
Plasma concentrations are simulated from the following l-compartment





The observations, $C_{mij}$, are simulated plasma concentrations of subject 1at time $t_{\mathrm{j}\dot{p}}$
after multiple $m$-dosing on the $\log$-scale to provide additive residual error. The times at
each multiple-dosing are fixed as [0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12,
24]. $\tau$ is fixed as 24. The observations on each individual are randomly selected from a
uniform distribution.
The fixed effects population parameters of interest are $k_{\theta}$, $VD$ and $CL$. The
parameter, $k_{a}$ , is an absorption rate constant, $VD$ is atotal distribution volume
constant and $CL$ is atotal body clearance rate constant. The individual-specific
constant, $k_{\epsilon i}$, $VD_{\mathrm{j}}$ and $CL_{\mathrm{j}}$, can be defined as lognormal random variables. The normal
random variables, ZCLi, $Z_{VDj}$ and $Z_{kg\mathrm{j}}$, which define $CL_{\mathrm{j}}$, $VD_{i}$ and $k_{sj}$ , are assumed to be
independent with mean zero and variances, CVCLy $CV_{VD}$ and $CV_{ka}$ , respectively. The
residual errors $e_{j},\cdot$ are assumed to be lognormally distributed and be independent $\mathrm{o}\mathrm{f}Z_{CIr}$
$Z_{VD\mathrm{j}}$ and $Z_{kg\mathrm{j}}$ with mean zero and variance $CV_{CP}$ Therefore, the variance parameters of
interest are $CV_{CL}$, CVVDi $CV_{*\iota}$ and $CV_{CP}$
We focus on the results derived from the $1^{\mathrm{s}\mathrm{t}}$ order Taylor expansion around $\hat{b}_{i}$ in this
paper. The results derived from the $1^{s\mathrm{t}}$ order Taylor expansion around the expected values, 0,
can be found in Minami, 2002. Table 3-1 shows the parameter values for each simulation
study on 15 scenarios. We perform simulations uP to “100” to obtain optimal
parameter estimates.
Table 3-1: Simulation Data Sets
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Equation (12) defines bias (%) for evaluation of the estimated fixed parameters from
the simulated data sets.
$Bias(^{0}/\mathit{0})$ $= \frac{\hat{\beta}-\beta_{0}}{\beta_{0}}\mathrm{x}1W$ (%) (12)
$\hat{\beta}$ :Parameter estimate of fixed effects
$\beta_{0}$ :True values of fixed effects
Table 3-2 and Figure 4-1 show results of the bias$(^{\mathrm{o}/\Phi})$ of $CL$ from 100 simulations
derived from the $1^{\epsilon \mathrm{t}}$ order Taylor expansion around $\hat{b}_{i}$ . In Figure 3-1, the symbol $(\blacksquare)$
denotes amean of the estimated parameters, $\hat{\beta}$ . The symbol (A) of atop or abottom
denotes amaximum or aminimum value of the bias(%) of $CL$ from 100 simulations,
and the symbol (X) of abottom or atop denotes 1% or 99% quantile, respectively. The
bottom and top edges of the box plots denote 25% and 75% quantiles. The line in an
interior of the box denotes amedian (50% quantile)
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Table 3-2: Results from the $1^{\mathrm{s}\mathrm{t}}$ order Taylor Expansion $\mathrm{a}\mathrm{r}\mathrm{o}\mathrm{u}\mathrm{n}\mathrm{d}\hat{b}_{i}$
Figure 3-1: Results from the $1^{\mathrm{s}\mathrm{t}}$ order Taylor expansion around $\hat{b}_{i}$
$N=25$ $N=50$ $N=100$
$\Leftrightarrow n_{j}=2$ , cal $n,=3$ , $\infty$ $n_{j}=4,$ $\subset\supset n_{j}=5,\tilde{\tilde{\mathrm{a}}}_{\tilde{\overline{\acute{m}}}}"/?,=6$
4. Conclusion
We investigate possible effects of required conditions regarding atotal sample size , $N$,
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and anumber observations per subject, $I\mathrm{J}_{j}$ on the estimated population parameters,
$\hat{\beta}$ , in an application of the two approximation approaches to the marginal distribution,
the $1^{\epsilon \mathrm{t}}$ order Taylor expansion around the expected values, 0, and around the
estimated random effects, $\hat{b}_{i}$ , in population pharmacokinetics studies.
Table 3-2 and Figure 3-1 show the effects of the approximation derived by the $1^{\epsilon \mathrm{t}}$
order Taylor expansion around the estimated random effects, $\hat{b}_{i}$ , on the estimated
population parameters, 7, by changing atotal sample size ($N=25,50$, and 100), and
anumber of observations per subject ($\mathrm{n}_{j}=2,3,4,5$ , to 6). On the condition that we
observe variability in the fitted curve, Varf$[b_{i}]$ , among subjects, Figure 3-1 indicates
that this approximation method produces unbiased population estimators. As the
number of observations per subject increase, the confidence interval decreases
accordingly. In comparison of the results from $N=25$ and from $N=\mathrm{I}\mathrm{O}\mathrm{O}$, the precision of
the estimated population parameters on anumber of observations per subject $\mathrm{w}\mathrm{i}\mathrm{U}$
depend on atotal number of subjects. For example, in the case of $N=25$, the
confidence interval decreases beyond $\mathrm{n}_{\mathrm{j}}=4$ . On the other hand, in the case of $N=1\mathrm{O}\mathrm{O}$ ,
the size of the confidence interval does not depend on anumber of observations per
subject. Equation (10) suggests these relationships. That is, the precision of the
estimated parameters will depend on aratio of the number of observations per subject
to the total number of subjects.
Minami, 2002 discussed the results derived from the approximation by the $1^{\epsilon \mathrm{t}}$ order
Taylor expansion around the expected values, 0when we can not ignore the variations
among subjects. The approximation produces biased estimators. The observed bias
does not depend on the number of observations per subject. But the confidence interval
of the estimators decrease as the total number of subjects increase within the same
number of observations per subject. The results suggest that for afixed total number
of observations, say, 200, it would be better that 2observations per subject are taken
from 100 subjects, instead, 4observations per subject are taken from 50 subjects to
produce asmaler confidence interval
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This paper investigated the characteristics of the two types of approximation
approaches to the marginal distribution of the observed data by the
$1^{\mathrm{s}\mathrm{t}}$ order Taylor
expansion when we observe the variability among subjects. The approximation
method by the $1^{\mathrm{s}\mathrm{t}}$ order Taylor expansion around the expected values, 0, produces
biased population parameter estimates, whose size of the confidence interval is subject
to anumber of subjects. On the other hand, the approximation method by the
$1^{\mathrm{s}\mathrm{t}}$ order
Taylor expansion around the estimated random effects produces unbiased estimators,
whose size of the confidence interval depends on aratio of anumber of observations
per subject to atotal number of subjects. In actual clinical practice, it is very difficult
to take many observations per subject, especially in phase III studies with possible
heterogeneity of study subjects, indicating the variability of responses among the
subjects. Therefore we have to deal with the problem by astudy design of population
pharmacokinetics studies. When we expect the variations, we should confine a
homogeneous population, for which we can sample data from the population by afew
number of observations per subject from many subjects. Otherwise many observations
per subject have to be sampled according to an appropriate total number of subjects
derived from equation (10).
We investigate agoodness of fit test to the observed data for the two types of the
approximation methods because actual clinical trial settings mostly will not allow the
conditions by either ignorable variation among subjects or the conditions by equation
(10).
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